April 28 Premarket Briefing: 10 Things You Should Know

Updated from 6:56 a.m. EDT.

Here are 10 things you should know for Monday, April 28:

1. 
-- U.S. stock futures were rising Monday and European stocks were higher on mergers-and-acquisitions news.

Asian shares ended mostly lower as tensions in Ukraine continued to rattle global markets. Japan's Nikkei 225 declined 1%.

2. -- The economic calendar in the U.S. on Monday includes pending-home sales for March at 10 a.m. EDT.

3. -- U.S. stocks on Friday traded lower amid rising tension in Ukraine.

The Dow Jones Industrial Average fell 0.81% to 16,361.78, while the S&P 500 lost 0.81% to close at 1,863.41. The Nasdaq tumbled 1.75% to 4,075.56. The Dow, S&P and Nasdaq for the week declined 0.29%, 0.08% and 0.49%, respectively.

4. -- AstraZeneca (AZN) shares soared in early trading on Monday after Pfizer (PFE) publicly disclosed details of a $100 billion bid approach.

PfiZer, the maker of Viagra, said Monday that AstraZeneca rejected an initial approach in January valuing the company at about 59 billion pounds ($100 billion). The cash and shares deal would represent a 30% premium on AstraZeneca's closing share price of 35.26 pounds on Jan. 3, the date of the offer.

The board of AstraZeneca on Monday issued a statement saying  "absent a specific and attractive proposal, it was not appropriate to engage in discussions with Pfizer." 

AstraZeneca said its "board remains confident in the ongoing execution of AstraZeneca's strategy as an independent company and that its successful delivery will create significant value for shareholders."

AstraZeneca rose 16.8% in premarket trading to $80.20; Pfizer rose 2% to $31.35.

5. -- France will block any deal involving engineering group Alstom it considers unfit, Economy Minister Arnaud Montebourg said ahead of a meeting between President Francois Hollande and General Electric (GE) CEO Jeff Immelt to discuss Alstom's future, Reuters reported.

If you liked this article you might like

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting

AstraZeneca Spikes After Lung Cancer Treat Study Shows 'Encouraging' Results